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ABSTRACT
Introduction: Prostate cancer (PC) is the sec-
ond leading cause of cancer death among US
men and accounts for considerable healthcare
expenditures. We evaluated economic out-
comes in men with chemotherapy-naı̈ve meta-
static castration-resistant PC (mCRPC) treated
with enzalutamide or abiraterone acetate plus
prednisone (abiraterone).
Methods: We performed a retrospective analy-
sis on 3174 men (18 years or older) utilizing the
Veterans Health Administration (VHA) database
from 1 April 2014 to 31 March 2018. Men with
mCRPC were included if they had at least one
pharmacy claim for enzalutamide or abi-
raterone (first claim date = index date) follow-
ing surgical or medical castration, had no
chemotherapy treatment within 12 months
prior to the index date, and had continuous
VHA enrollment for at least 12 months pre- and
post-index date. Men were followed until death,
disenrollment, or end of study and were 1:1
propensity score matched (PSM). All-cause and
PC-related resource use and costs per patient per
month (PPPM) in the 12 months post index
were compared between matched cohorts.
Results: We identified 1229 men with mCRPC
prescribed enzalutamide and 1945 prescribed
abiraterone with mean ages of 74 and 73 years,
respectively. After PSM, each cohort had 1160
patients. The enzalutamide cohort had fewer
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all-cause (2.51 vs 2.86; p\ 0.0001) and PC-re-
lated outpatient visits (0.86 vs 1.03; p\ 0.0001),
with corresponding lower all-cause ($2588 vs
$3115; p\0.0001) and PC-related ($1356 vs
$1775; p\0.0001) PPPM outpatient costs
compared with the abiraterone cohort. All-
cause total costs (medical and pharmacy) PPPM
($8085 vs $9092; p = 0.0002) and PC-related
total costs PPPM ($6321 vs $7280; p\ 0.0001)
were significantly lower in the enzalutamide
cohort compared with the abiraterone cohort.
Conclusions: Enzalutamide-treated men with
chemotherapy-naı̈ve mCRPC had significantly
lower resource utilization and healthcare costs
compared with abiraterone-treated men.
Plain Language Summary: Plain language
summary available for this article.
Keywords: Abiraterone acetate; Enzalutamide;
Healthcare costs; Prostate cancer; Survival
Key Summary Points
Why carry out this study?
Prostate cancer treatment can incur
significant costs due to hospitalizations,
outpatient visits, and treatment
medications including prescriptions to
treat adverse events related to treatment.
Limited real-world data have been
published evaluating the treatment costs
of secondary antiandrogen therapies
enzalutamide and abiraterone acetate




What did the study ask?
We evaluated economic outcomes in men
with chemotherapy-naı̈ve mCRPC treated
with enzalutamide or abiraterone in the
Veterans Health Administration (VHA)
database to determine if the healthcare
resource utilization (HCRU) and costs
were different between enzalutamide- and
abiraterone-treated patients.
What were the study outcomes/
conclusions?
Men with chemotherapy-naı̈ve mCRPC
treated with enzalutamide had less HCRU
and incurred lower total healthcare costs
than those treated with abiraterone.
What has been learned from the study?
This is the first study to report real-world
data on the HCRU and costs for patients
with chemotherapy-naı̈ve mCRPC taking
enzalutamide and abiraterone using the
VHA database, which includes a large
patient population that is distinct from
patients enrolled in clinical trials or who
are commercially insured.
These results support the hypothesis that
the long-term HCRU and costs of
enzalutamide may be lower compared
with abiraterone.
PLAIN LANGUAGE SUMMARY
Prostate cancer (PC) is the second leading cause
of death among men with cancer in the USA.
Healthcare costs associated with PC, including
hospitalizations, outpatient visits, and medica-
tions prescribed to treat adverse effects, depend
on the severity of the disease and intensity of
treatment, but are generally very high. Enzalu-
tamide and abiraterone acetate with prednisone
(abiraterone) are both approved treatments for
men with PC that does not respond to treat-
ments that reduce the male hormone testos-
terone, known as castration-resistant PC
(CRPC). These drugs are associated with varying
treatment duration and different adverse
effects, and therefore could result in differences
in the use of healthcare resources and overall
cost of treatment. Here we evaluated the
healthcare resource utilization (HCRU), which
was calculated as the average number of
healthcare encounters, including inpatient
stays, outpatient visits, and pharmacy visits,
and length of inpatient stays, and treatment
costs associated with use of enzalutamide or
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abiraterone by men with metastatic CRPC
(mCRPC), who had not received prior
chemotherapy in the Veterans Health Admin-
istration. We found that men with chemother-
apy-naı̈ve mCRPC treated with enzalutamide
used less healthcare resources and incurred
lower total healthcare costs than men treated
with abiraterone. On average, all-cause total
healthcare costs were $1007 per patient per
month lower and PC-related total healthcare
costs were $959 per patient per month lower for
patients treated with enzalutamide than those
treated with abiraterone. These results support
the hypothesis that the long-term HCRU and
costs of enzalutamide may be lower compared
with abiraterone.
INTRODUCTION
Prostate cancer (PC) is the most common
malignancy and the second leading cause of
cancer-related death among men in the USA. An
estimated 174,650 new cases of PC will be
diagnosed in the USA in 2019, with 31,620
deaths [1, 2]. PC cost the Medicare system over a
3-year period (2004 to 2007) about $1.2 billion
in 2013 US dollars [3]. The cost depends on the
severity of disease and the intensity of treat-
ment. Within 5 years of follow-up, approxi-
mately 10–20% of all patients with PC develop
castration-resistant PC (CRPC) [4], defined as PC
that progresses despite the use of androgen
deprivation therapy by surgical or medical cas-
tration. The majority of these patients (84%)
demonstrate radiographic findings of metastatic
CRPC (mCRPC), and at least 5% will progress
from nonmetastatic CRPC to mCRPC within
2 years [5]. Patients with mCRPC account for
approximately 10% of all PC cases [6]. Currently
there are no curative treatment options avail-
able; therefore, the prognosis is poor, with an
estimated overall survival of less than 3 years
[4, 7, 8].
Docetaxel was the standard of care to treat
mCRPC until the introduction of two androgen
pathway-targeted treatments, enzalutamide (a
second-generation androgen receptor inhibitor)
and abiraterone acetate (an irreversible
CYP17A1 inhibitor) combined with prednisone
(abiraterone). These two agents received US
Food and Drug Administration approval for use
in mCRPC after docetaxel in August 2012 and
April 2011, respectively, and then in
chemotherapy-naı̈ve mCRPC in September
2014 and December 2012, respectively [9].
Enzalutamide and abiraterone have delayed
deterioration of health-related quality of life
and increased survival for patients with
chemotherapy-naı̈ve mCRPC in clinical trial
settings [10, 11].
Clinical trials are informative in assessing
efficacy and safety of treatments, but it is
important to evaluate their impact on patient
outcomes as well as payers in the real-word
setting. Furthermore, it is anticipated that
treatments will differ in healthcare resource
utilization (HCRU) and costs, e.g., due to dis-
parate treatment duration and adverse event
profiles [10–12]. Abiraterone is administered
together with prednisone, a corticosteroid that
is used to reduce treatment-related symptom
burden. Corticosteroids have been shown to be
associated with toxicities, such as adrenal sup-
pression, diabetes, osteoporosis, myopathy,
infection, hypertension, glaucoma, and cardio-
vascular disease [13–16], with increased cost
from cumulative exposure [17]. However, out-
comes like HCRU and costs are usually not
collected within clinical trials, and when col-
lected, would reflect outcomes of a generally
younger population with fewer comorbidities
that are closely monitored. Similar to efficacy
and safety outcomes, HCRU and costs are
therefore expected to be different in a clinical
practice setting, highlighting the need for real-
world evidence generation.
Very few real-world studies have assessed
HCRU and costs of novel therapies in mCRPC in
the USA. A recent study, using real-world data
from patients with chemotherapy-naı̈ve
mCRPC in a commercially insured population,
reported lower HCRU and PC-related inpatient
and emergency department costs for enzalu-
tamide compared with abiraterone [18].
Another recent real-world study described
treatment patterns, healthcare costs, and sur-
vival in patients with mCRPC who were com-
mercially insured or Medicare covered and
showed that enzalutamide and abiraterone were
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the most common first-line treatments (more
than 65% in total); however, no direct cost
comparisons between the treatments were
reported [19].
The cost of treatments to noncommercially
insured populations such as the Veterans Health
Administration (VHA) has not been investi-
gated. The VHA is the largest integrated
healthcare system in the USA and represents a
different patient population than most com-
mercial claims databases or fee-for-service
Medicare, with more racial minorities and more
patients who reside in lower-income areas [20].
Treatment patterns have also been shown to
differ in the VHA compared with commercially
insured patients [20]. PC is the most common
cancer diagnosis among male US veterans [21].
In 2014, the incidence of newly diagnosed PC
was 12,000, and the prevalence rate of sur-
vivorship was 200,000 [22].
This study was designed to compare HCRU
and costs in patients with chemotherapy-naı̈ve
mCRPC treated with enzalutamide or abi-
raterone in the VHA database. Our study
addresses important gaps in the literature and
contributes additional real-world evidence on
key outcomes in patients with mCRPC treated
with secondary antiandrogen therapy in the
first-line setting. The study also assessed sur-
vival differences between enzalutamide and




In this retrospective observational study,
enrollment, inpatient, outpatient, and phar-
macy data were captured from 1 April 2013 to
31 March 2018 in the VHA database. Medical
claims included diagnosis and procedure codes
from the International Classification of Dis-
eases, Ninth and Tenth Revisions, Clinical
Modification (ICD-9-CM and ICD-10-CM),
Current Procedural Terminology, Version 4
procedure codes, and Healthcare Common
Procedure Coding System codes. Outpatient
pharmacy claims included National Drug Codes
for dispensed medications. This study was
exempt from institutional review board assess-
ment because there was no extraction or use of
any personally identifiable information.
Patient Identification
Eligible patients (18 years or older) had at least
one medical claim with a diagnosis code for PC
(ICD-9-CM: 185, ICD-10-CM: C61), evidence of
surgical or medical castration, and a prescrip-
tion claim for abiraterone or enzalutamide after
castration at any time during the study. The first
claim for enzalutamide or abiraterone between
1 April 2014 and 31 March 2018 was designated
as the index date. Patients were required to have
continuous VHA enrollment for at least
12 months pre- (baseline period) and at least
12 months post-index date (follow-up period)
and were followed until the earliest occurrence
of either death, disenrollment, or end of study.
To ensure patients were newly initiating treat-
ment, those with prescription claims for abi-
raterone or enzalutamide or who had other
types of cancers during the pre-index period
were excluded from the study.
Patient Characteristics
Demographic characteristics (age and race) were
examined on the index date and clinical char-
acteristics, including modified Quan–Charlson
comorbidity index (CCI) scores, individual
comorbidities (urinary tract infection, impo-
tence, breast disorders, hypertension, stroke,
angina pectoris perforation, arrhythmia, con-
gestive heart failure, hyperlipidemia, low-ex-
tremity arterial occlusive disease, type 2
diabetes, liver damage/abnormality, acute
coronary syndrome/myocardial infarction), and
prior prostate cancer treatments, were measured
during the pre-index period.
HCRU and Costs
All-cause and PC-related HCRU and costs were
evaluated for both cohorts during a 12-month
post-index period. HCRU and costs were con-
sidered PC-related if there was an observed ICD-
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9/ICD-10 PC diagnosis in a primary or sec-
ondary position on the medical claim. All-cause
and PC-related HCRU were calculated as the
average number of healthcare encounters, cat-
egorized as inpatient stays, outpatient visits,
and pharmacy visits. All-cause and PC-related
costs were calculated as inpatient stay costs,
outpatient visit costs, pharmacy visit costs, total
medical costs (sum of inpatient and outpatient
visit costs), and total costs (sum of medical and
pharmacy visit costs) adjusted to 2018 US dol-
lars using the medical care component of the
Consumer Price Index [24].
Statistical Analysis
Demographic and baseline clinical characteris-
tics and HCRU costs were compared between the
enzalutamide and abiraterone cohorts using
standard descriptive statistics. For continuous
variables, p values were obtained using Student’s
t tests; for categorical variables, p values were
obtained using Chi-squared tests. HCRU and
costs were measured on a per patient per month
(PPPM) basis during the 12 months post-index
period. A sensitivity analysis was also performed
using the end of the study as the end date rather
than the 12-month follow-up. An additional
analysis also evaluated outcomes in patients
after treatment discontinuation with enzalu-
tamide or abiraterone to the end of the study.
Propensity Score Matching
To adjust for potential selection bias, the study
cohorts were matched using the propensity
score matching (PSM) method, a statistical
regression approach to remove major con-
founding influences on outcome assessment.
These influential factors may be from patients’
clinical history or baseline characteristics, lar-
gely leading to patient selection bias. Patients in
the enzalutamide and abiraterone cohorts were
1:1 matched using a greedy 5 ? 3-digit match
based on an allowable absolute difference
between propensity scores of 0.01. Propensity
scores were calculated in a logistic regression
model controlling for baseline age, race,
Quan–CCI score, and comorbidities.
Standardized mean differences (SMDs), calcu-
lated as the difference in mean of a baseline
variable between the two cohorts divided by the
standard deviation of the variable, were used to
check for balance in adjusted characteristics
[25]. We selected a threshold of 10 to assess
balance, in accordance with the methodology
of previous studies [26, 27]. In addition, stan-
dardized differences are indicative of practi-
cal/clinical significance; for this purpose, SMDs
greater than 10 are indicative of practically sig-
nificant differences between the treatment
cohorts.
All statistical analyses were performed using
SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
RESULTS
A total of 5685 patients with mCRPC were
identified with a prescription of enzalutamide
or abiraterone. After exclusion of patients
diagnosed with other types of cancer pre-index
and patients with evidence of chemotherapy
pre-index, 3174 patients (55.8%) were included,
1229 in the enzalutamide cohort and 1945 in
the abiraterone cohort (Fig. 1).
Baseline Characteristics
Demographic and baseline clinical characteris-
tics are listed in Table 1. On average, patients in
the enzalutamide cohort were older than
patients in the abiraterone cohort (74 years vs
73 years; p = 0.0112). Enzalutamide-treated
patients were more likely to have comorbid
conditions, including arrhythmia (8.87% vs
5.60%; p = 0.0004), congestive heart failure
(9.85% vs 6.43%; p = 0.0005), and type 2 dia-
betes (35.15% vs 29.56%; p = 0.0010).
After PSM, 1160 enzalutamide-treated
patients were matched 1:1 with abiraterone-
treated patients; both cohorts were well bal-
anced on baseline characteristics (Table 1).
Healthcare Resource Utilization
All-cause and PC-related HCRU were mostly
lower for enzalutamide-treated compared with
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abiraterone-treated patients during the
12-month post-index period (Fig. 2a, b and
Table 2). Enzalutamide-treated patients had
significantly fewer all-cause outpatient visits
PPPM (2.51 vs 2.86; p\0.0001) and fewer all-
cause pharmacy visits PPPM (2.95 vs 3.19;
p\0.0001). There were fewer PC-related inpa-
tient stays PPPM (0.04 vs 0.05; p = 0.0317),
shorter inpatient length of stay (in days) PPPM
(0.45 vs 0.63; p = 0.0291), and fewer outpatient
visits PPPM (0.86 vs 1.03; p\ 0.0001) in the
enzalutamide cohort compared with the abi-
raterone cohort. For PC-related inpatient stays
and length of stay, the SMDs were less than 10,
indicating that the results were not practically
significant. All-cause number of and inpatient
length of stay (days) and PC-related number of

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































pharmacy visits PPPM were similar between the
cohorts.
Healthcare Costs
All-cause and PC-related healthcare costs were
lower for enzalutamide-treated compared with
abiraterone-treated patients 12 months post
index (Fig. 2c, d and Table 2). Patients in the
enzalutamide cohort incurred significantly
lower all-cause outpatient costs PPPM ($2588 vs
$3115; p\ 0.0001), total medical costs PPPM
($3907 vs $4800; p = 0.0003), and total costs
PPPM ($8085 vs $9092; p = 0.0002). In both
cohorts, PC-related costs accounted for a large
proportion (ca. 80%) of the all-cause costs. PC-
related inpatient costs PPPM ($929 vs $1389;
p = 0.0079), outpatient visit costs PPPM ($1356
vs $1775; p\0.0001), total medical costs PPPM
($2285 vs $3164; p\0.0001), and total costs
PPPM ($6321 vs $7280; p\0.0001) were sig-
nificantly lower in the enzalutamide cohort
compared with the abiraterone cohort. The
proportion of patients who crossed over to the
respective treatments (i.e., abiraterone followed
by enzalutamide, 26%; enzalutamide followed
by abiraterone, 23%) or followed first-line
treatment with chemotherapy (abiraterone fol-
lowed by chemotherapy, 9.2%; enzalutamide
followed by chemotherapy, 6.3%) was similar.
Sensitivity Analyses
In a sensitivity analysis evaluating outcomes
during the full study period, the median follow-
up was 18.4 months (range 0.1–48.2) for the
Fig. 2 All-cause (a) and PC-related (b) HCRU and all-
cause (c) and PC-related (d) costs among patients with
chemotherapy-naı̈ve mCRPC treated with enzalutamide or
abiraterone after PSM from index date through the
12-month follow-up period. HCRU healthcare resource
utilization, mCRPC metastatic castration-resistant prostate
cancer, PC prostate cancer, PPPM per patient per month,
PSM propensity score matching
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Table 2 Economic outcomes among patients with chemotherapy-naı̈ve mCRPC treated with enzalutamide or abiraterone
after PSM from the index date through the 12-month follow-up period





All-cause healthcare resource utilization
Any inpatient stay, n (%) 291 (25.09) 334 (28.79) 0.0442 8.36
Any outpatient visit, n (%) 1149 (99.05) 1157 (99.74) 0.0320 8.91
Any pharmacy visit, n (%) 1160 (100.00) 1160 (100.00) NA 0.00
Inpatient length of stay (in days), PPPM ± SD 0.61 ± 2.24 0.74 ± 2.43 0.1893 5.45
Number of inpatient stays, PPPM ± SD 0.05 ± 0.13 0.06 ± 0.14 0.0815 7.24
Number of outpatient visits, PPPM ± SD 2.51 ± 1.61 2.86 ± 1.69 \ 0.0001 20.94
Number of pharmacy visits, PPPM ± SD 2.95 ± 1.53 3.19 ± 1.48 \ 0.0001 16.32
PC-related healthcare resource utilization
Any inpatient stay, n (%) 232 (20.00) 289 (24.91) 0.0046 11.79
Any outpatient visit, n (%) 1072 (92.41) 1089 (93.88) 0.1624 5.80
Any pharmacy visit, n (%) 1160 (100.00) 1160 (100.00) NA 0.00
Inpatient length of stay (in days), PPPM ± SD 0.45 ± 1.68 0.63 ± 2.27 0.0291 9.06
Number of inpatient stays, PPPM ± SD 0.04 ± 0.12 0.05 ± 0.13 0.0317 8.93
Number of outpatient visits, PPPM ± SD 0.86 ± 0.72 1.03 ± 0.76 \ 0.0001 22.90
Number of pharmacy visits, PPPM ± SD 0.86 ± 0.53 0.87 ± 0.34 0.3243 4.09
Mean all-cause healthcare costs, US$
Inpatient stay costs, PPPM ± SD 1319 ± 5030 1686 ± 5567 0.0958 6.92
Outpatient visit costs, PPPM ± SD 2588 ± 2238 3115 ± 2428 \ 0.0001 23.03
Pharmacy visit costs, PPPM ± SD 4178 ± 3161 4291 ± 2059 0.3091 4.22
Total medical (inpatient ? outpatient) costs,
PPPM ± SD
3907 ± 5679 4800 ± 6284 0.0003 14.92
Total (medical ? pharmacy) costs, PPPM ± SD 8085 ± 6495 9092 ± 6676 0.0002 15.29
Mean PC-related healthcare costs, US$
Inpatient stay costs, PPPM ± SD 929 ± 3314 1389 ± 4871 0.0079 11.03
Outpatient visit costs, PPPM ± SD 1356 ± 1560 1775 ± 1910 \ 0.0001 24.03
Pharmacy visit costs, PPPM ± SD 4037 ± 3154 4117 ± 2044 0.4669 3.02
Total medical (inpatient ? outpatient) costs,
PPPM ± SD
2285 ± 3870 3164 ± 5312 \ 0.0001 18.91
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enzalutamide cohort and 19.1 months (range
0.4–48.7) for the abiraterone cohort. All-cause
total costs PPPM were lower overall than in the
12-month follow-up period [mean all-cause
costs were $8085 vs $9092 for the enzalutamide
cohort vs the abiraterone cohort in the
12-month follow-up (Table 2) compared with
$7643 vs $8520 in the full follow-up] (Table S1
in the supplementary material). The enzalu-
tamide cohort had in general lower all-cause
and PC-related HCRU and lower all-cause and
PC-related costs than the abiraterone cohort
(Table S1).
There were 667 patients in the enzalutamide
cohort and 744 in the abiraterone cohort who
discontinued treatment during the study per-
iod. There were significantly fewer all-cause
outpatient visits PPPM in the enzalutamide
cohort compared with the abiraterone cohort
(2.61 vs 2.81, respectively; p = 0.0381). The
remaining all-cause and PC-related HCRU out-
comes were generally similar between the two
cohorts (Table S2 in the supplementary mate-
rial). Lower cost trends were observed for the
enzalutamide cohort regarding all-cause and
PC-related costs. However, there were signifi-
cantly lower PC-related pharmacy ($1252 vs
$1492; p = 0.0033) and PC-related total costs
PPPM ($3755 vs $4256; p = 0.0496) in the
enzalutamide cohort (Table S2).
DISCUSSION
This retrospective cohort study using recent
real-world data from the VHA database provides
evidence that enzalutamide-treated patients
with chemotherapy-naı̈ve mCRPC had lower
HCRU and incurred lower healthcare costs than
abiraterone-treated patients. Patient demo-
graphics and baseline characteristics were con-
sistent with the demographic profile of patients
enrolled in the VHA [28] and align with the
mean ages reported in clinical studies of
mCRPC [10, 11, 29, 30]. However, our study
included a higher proportion of black patients
compared with clinical trials [10, 11, 29, 30],
reflecting the more diverse nature of the VHA
database.
There were fewer all-cause outpatient and
pharmacy visits for enzalutamide-treated
patients compared with abiraterone-treated
patients. Schultz et al. also found that treatment
with enzalutamide, despite a higher occurrence
of comorbid conditions, was associated with
fewer inpatient and emergency department
visits than abiraterone, likely attributed to cor-
ticosteroid use among abiraterone-treated
patients [18]. In our PSM-matched cohorts,
more abiraterone-treated patients used corti-
costeroids during the pre-index period than did
enzalutamide-treated patients (45.69% vs
26.90%, respectively). Prednisone is prescribed
concurrently with abiraterone to reduce occur-
rence of adverse events but is associated with
immunosuppression, higher rate of infections,
and more serious adverse events and comor-
bidities [7]. The difference in corticosteroid use
pre-index could indicate that physicians chose
to prescribe abiraterone to patients who were
already taking corticosteroids for an unrelated
comorbidity. Treatment of these corticosteroid-
sensitive comorbidities could require frequent
outpatient or pharmacy visits for abiraterone-
treated patients and may explain why enzalu-
tamide-treated patients had lower HCRU
[11, 31]. Cumulative use of corticosteroids
Table 2 continued





Total (medical ? pharmacy) costs, PPPM ± SD 6321 ± 5007 7280 ± 5708 \ 0.0001 17.87
Values in italics indicate statistically significant differences between cohorts. SMDs[ 10 indicate practically/clinically
significant differences between cohorts
mCRPC metastatic castration-resistant prostate cancer, PC prostate cancer, NA not applicable, PPPM per patient per
month, PSM propensity score matching, SD standard deviation, SMD standardized mean difference
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before CRPC treatment initiation has also been
shown to be associated with higher HCRU and
costs [17].
Our study showed that enzalutamide-treated
patients also had lower all-cause and PC-related
healthcare costs. Massoudi et al. estimated that
within a 1-year time horizon, the total cost per
patient was $2666 lower in the enzalutamide
arm compared with the abiraterone arm in a
model based on clinical trial data [32]. The cost
difference in our study was much larger (a dif-
ference of approximately $12,000 for all-cause
and PC-related costs per year). Our results were
based on real-world data including patients who
may not be eligible for clinical trials, which may
have led to more frequent HCRU and higher
costs compared with a model based on a
healthier patient population. Findings of lower
all-cause emergency room and PC-related inpa-
tient costs in enzalutamide-treated patients
have also been previously reported, although
these patients incurred higher all-cause and PC-
related pharmacy costs [18], whereas in our
study, enzalutamide-treated patients had lower
costs in all categories.
Enzalutamide and abiraterone have different
toxicity profiles that will affect HCRU and costs
differently. However, we present aggregate
medical costs as accrued in the VA claims sys-
tem and did not examine the specific cause of
HCRUs and costs. There is limited information
on toxicity-related costs with these agents. An
administrative claims study, looking at mCRPC
patients without differentiating between
chemotherapy-naı̈ve and post-chemotherapy
patients, showed that there was a higher likeli-
hood of having a broadly defined central ner-
vous system (CNS) event with enzalutamide
compared with abiraterone [33]. In a separate
administrative claims study in a nonmetastatic
prostate cancer population, CNS-related adverse
events were associated with higher per patient
per year HCRU with respect to inpatient and
emergency department visits versus patients
without CNS adverse events; however, no direct
association with different drug treatment was
reported as most patients were treated with
bicalutamide (n = 477) and only a few patients
on abiraterone or enzalutamide (n = 55) were
included [34]. Other adverse event-related costs
with second-generation androgen therapy, such
as for cardiac disorder, infection, pneumonia,
renal impairment, skeletal-related events, uri-
nary tract infection, etc., have to our knowledge
not been studied. Further research into the rel-
ative impact of adverse events of interest with
the treatment of enzalutamide or abiraterone is
warranted.
Given that about 75% of patients with
mCRPC have overall survival longer than
12 months after initiation of abiraterone [35],
we examined HCRU and costs until death or the
end of study. All-cause and PC-related PPPM
HCRU and costs overall were lower in the full
follow-up period than in the first year of follow-
up, mainly owing to lower pharmacy costs. This
suggests that patients with mCRPC utilize more
health services in the first year post-therapy
initiation. Nonetheless, HCRU and costs were
still found to be lower among enzalutamide-
treated patients compared with abiraterone-
treated patients.
All-cause and PC-related HCRU and costs
post discontinuation until the end of follow-up
were also assessed among patients who discon-
tinued. Results exhibited that all-cause and PC-
related HCRU and costs were also lower for
enzalutamide-treated patients compared with
abiraterone-treated patients. We did not assess
what treatments were used post discontinua-
tion, but the lower pharmacy costs are likely
explained by use of low cost chemotherapy in
later lines and limited PC drug treatment at the
final stage of disease. Future studies should
observe HCRU and costs pre- and post-switch-
ing among patients who experienced disease
progression to reveal important information on
the cost of disease progression.
Limitations
Findings of this study are subject to inherent
limitations of administrative claims databases,
such as coding errors or diagnoses entered for
administrative processing rather than clinical
completeness. Medications filled over-the-
counter or provided as samples by the physician
are not observed in the claims data. The pres-
ence of a diagnosis code on a medical claim
Adv Ther
does not necessarily indicate a positive presence
of disease. The general applicability of our
findings to younger patients requires further
study. Although we adjust for differences in
baseline patient characteristics to the extent
possible, we cannot exclude that biases in pre-
scribing patterns not revealed by these claims
data could account for differences in prognosis,
tolerance, and outcomes. We did not delineate
what costs were attributable to the use of
enzalutamide or abiraterone, for instance whe-
ther or not hospital visits were treatment related
or unrelated to enzalutamide or abiraterone.
Also, this analysis was completed at a time
when abiraterone was still patent protected.
Pricing of generic equivalents may alter cost
analyses in future studies.
CONCLUSIONS
Among VHA patients with mCRPC, those trea-
ted with enzalutamide had less HCRU and
incurred lower healthcare costs (on average
$1007 PPPM for all-cause and $959 PPPM for
PC-related total costs) than patients treated
with abiraterone, supporting the hypothesis
that the long-term costs and HCRU of enzalu-
tamide may be lower compared with abi-
raterone. Additional studies within other
healthcare settings are needed to provide a
more complete picture of the resource use and
costs in mCRPC patients treated with enzalu-
tamide and abiraterone.
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